Yahoo Finance Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape
With a handful of novel therapies emerging this year, pharmaceuticals have a lot more potential to explore in the field of Genital Warts.
Los Angeles, July 26, 2021 (GLOBE NEWSWIRE) -- Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape
With a handful of novel therapies emerging this year, pharmaceuticals have a lot more potential to explore in the field of Genital Warts.
DelveInsight’s ‘Genital Warts Pipeline Insight, 2021’ report offers an exhaustive global coverage of the available marketed therapies, Genital Warts pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Genital Warts pipeline domain.
Some of the major pointers taken from the Genital Warts Pipeline report:
DelveInsight’s analysis presents Genital Warts Pipeline with 6+ active players in the domain investigating 6+ pipeline therapies.
Major companies such as pHion Therapeutics, Orgenesis, KinoPharma, Novan, Cassiopeia, Innovax, Verrica Pharmaceuticals and others are developing potential drug candidates to improve the Genital Warts treatment scenario.
Key Genital Warts pipeline therapies such as PTX_V1, Anti-DNA Virus Program, Ranpirnase, SB 207, CB-06-02, VP-102, HPV Vaccine and others are under investigation in different phases of clinical trials for the treatment of Genital Warts.
On March 17, 2021, Verrica entered into a License Agreement with Torii Pharmaceutical Co. Ltd. granting Torii an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.
Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Genital Warts Emerging Therapies and Forecast
The Genital Warts pipeline report offers detailed profiles of the pipeline assets along with the inactive and dormant assets, comparative analysis of clinical and non-clinical stage Genital Warts products, comprehensive assessment of driving and restraining factors along with the opportunities and risks in the Genital Warts pipeline landscape.
Genital Warts (condyloma acuminatum) are the clinical manifestations of a sexually transmitted infection caused by HPV. The four morphologic types of genital warts are cauliflower-shaped, smooth papular, keratotic, and flat. It is estimated that anywhere between 500,000 to one million new cases are diagnosed each year in the United States alone, with clinically apparent warts presenting in approximately one percent of the sexually active population.
Discover more about the disease, treatments, and pipeline therapies @ Genital Warts Pipeline Assessment
Genital Warts Pipeline Drugs
Drug | Company |
PTX_V1 | pHion Therapeutics |
Anti-DNA Virus Program | KinoPharma |
Ranpirnase | Orgenesis |
SB 207 | Novan |
CB-06-02 | Cassiopea |
VP-102 | Verrica Pharmaceuticals |
HPV Vaccine | Xiamen Innovax Biotech |
Request for Sample to know more @ Genital Warts Pipeline Analysis, Key Companies, and Futuristic Trends
Genital Warts Therapeutics Assessment
The Genital Warts Pipeline report proffers an integral view of the Genital Warts emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
Mono
Combination
By Route of Administration
Subcutaneous
Intravenous
Oral
Inhalation
By Molecule Type
Gene therapy
Stem cell therapy
Small molecules
By Stage
Discovery
Pre-clinical
Phase I
Phase II
Phase III
By Mechanism of Action
Protease inhibitor
Immunomodulatory
Multiple kinase inhibitor
By Targets
Protease
Immune System
Scope of the Genital Warts Pipeline Report
Coverage: Global
Major Players: pHion Therapeutics, Orgenesis, KinoPharma, Cassiopeia, Innovax, Verrica Pharmaceuticals and others
Key Genital Warts Pipeline Theraṣpies: PTX_V1, Anti-DNA Virus Program, SB 207, CB-06-02, VP-102 and HPV Vaccine
For rich insights into emerging therapies and assessment, visit Genital Warts Pipeline Emerging Novel Therapies
Table of Contents
1 | Report Introduction |
2 | Executive Summary |
3 | Genital Warts: Overview |
4 | Genital Warts- Analytical Perspective In-depth Commercial Assessment |
5 | Pipeline Therapeutics |
6 | Late Stage Products (Phase III) |
7 | Mid Stage Products (Phase II) |
7.1 | Comparative Analysis |
7.2 | VP-102: Verrica Pharmaceuticals |
8 | Mid Stage Products (Phase II) |
8.1 | Comparative Analysis |
8.2 | CB-06-02: Cassiopea |
9 | Mid Stage Products (Phase II) |
9.1 | Comparative Analysis |
9.2 | SB 207: Novan |
10 | Early Stage Products (Phase I/II) |
11 | Early Stage Products (Phase I) |
12 | Pre-clinical and Discovery Stage Products |
13 | Therapeutic Assessment |
14 | Inactive Products |
15 | Company-University Collaborations (Licensing/Partnering) Analysis |
16 | Genital Warts Key Companies |
17 | Genital Warts Key Products |
18 | Genital Warts- Unmet Needs |
19 | Genital Warts- Market Drivers and Barriers |
20 | Genital Warts- Future Perspectives and Conclusion |
21 | Genital Warts Analyst Views |
22 | Appendix |
23 | About DelveInsight |
Discover more about the scope of the report @ Genital Warts Emerging Therapies, Treatments, and Ongoing Clinical Trials
Audit the market before venturing with DelveInsight’s Due Diligence Services
Related Reports
DelveInsight's "Genital Warts (Genital Warts) Market Insights, Epidemiology and Market Forecast-2030" report.
DelveInsight's "Common Warts (Common Warts), HPV infection Pipeline Insights” report.
DelveInsight's "Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast-2030" report.
Cervical Intraepithelial Neoplasia Market
DelveInsight's "Cervical Intraepithelial Neoplasia Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Cystitis Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight’s ‘Dysmenorrhea-Market Insights, Epidemiology and Market Forecast-2030’ report.
DelveInsight's "Erectile Dysfunction - Market Insights, Epidemiology, and Market Forecast-2030" report.
Browse through our Blog Posts
With at least half of the world’s population as women and over 100 startups leveraging technology to bring novel devices to help women through different biological stages such as menstruation, pregnancy, breastfeeding, and others, the FemTech market offers ample growth opportunities.
The contribution of key pharma companies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size.
Discover how Wearable devices are transforming healthcare delivery.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
